

786-0
293F:cynoCD70
293F (parental)
CD70 ECD
flag-CD70 ECD
SG-21.1C1
148
98
64
50
36
22
16
786-0
293F:cynoCD70
293F (parental)
CD70 ECD
flag-CD70 ECD
SG-21.5D12
148
98
64
50
36
22
16
786-0
293F:cynoCD70
293F (parental)
CD70 ECD
flag-CD70 ECD
SG-21.2B3

Figure 1




Figure 2




Figure 3




Figure 4



Normal Pancreas
Pancreatic Cancer
negative
Tumor cells +
Tumor Cells –
Stroma +

Figure 5



Pancreas - 35/140 (25%) positive
% area positive
100
75
50
25
0
0
1
2
3
4
5
Staining Intensity
6
1
3
1
2
3
1
3
2
5
3
5

Figure 6



Ovary - 37/241 (15%) positive
% area positive
100
75
50
25
0
0
1
2
3
4
5
Staining Intensity
4
10
5
5
6
3
2
1
1

Figure 7



SKOV-3
% of Control
120
100
80
60
40
20
0
10^-6
10^-5
10^-4
10^-3
10^-2
10^-1
10^0
10^1
10^2
[Compound], uM or ug/ml
h1F6vc-MMAF(4)
h1F6mcF4
h1F6mc-MMAF(8)
h1F6vc-MMAE(4)
MMAF
Non-binding ADC
Mitomycin C
h1F6

Figure 8



A.
HPAFII-cynoCD70
(2,000 cells/well) 96 hours
% of untreated
[ADC], ng/mL
IC50=178ng/mL
SGN-75
non-binding control ADC
B.
PANC-1/cynoCD70
(6 day assay)
% of untreated
[ADC], ng/mL
IC50=83ng/mL
PANC-1/cynoCD70
PANC-1

Figure 9

C.



MiaPaCa-2/cynoCD70
(5 day assay)
% of untreated
125
100
75
50
25
0
0.1
10
1000
100000
[ADC], ng/mL
IC50=29ng/mL
MiaPaCa-2/cynoCD70
MiaPaCa-2

Figure 9



B
Percent survival
Days for tumor to reach 800 mm3
Untreated
SGN-75 3 mg
Non-binding A
mg/kg
Dosing
Median Tumor volume (mm3)
Days Post Tumor Implant

Fig 10